The canonical pathogenesis of Alzheimer's disease links the expression of apolipoprotein E e4 allele (ApoE) to amyloid precursor protein (APP) processing and Aβ peptide accumulation by a set of mechanisms that is incompletely defined. The development of a simple system that focuses not on a single variable but on multiple factors and pathways would be valuable both for dissecting the underlying mechanisms and for identifying candidate therapeutics. Here we show that, although both ApoE3 and ApoE4 associate with APP with nanomolar affinities, only ApoE4 significantly (i) reduces the ratio of soluble amyloid precursor protein alpha (sAPPα) to Aβ; (ii) reduces Sirtuin T1 (SirT1) expression, resulting in markedly differing ratios of neuroprotective SirT1 to neurotoxic SirT2; (iii) triggers Tau phosphorylation and APP phosphorylation; and (iv) induces programmed cell death. We describe a subset of drug candidates that interferes with the APP-ApoE interaction and returns the parameters noted above to normal. Our data support the hypothesis that neuronal connectivity, as reflected in the ratios of critical mediators such as sAPPα:Aβ, SirT1:SirT2, APP:phosphorylated (p)-APP, and Tau:p-Tau, is programmatically altered by ApoE4 and offer a simple system for the identification of program mediators and therapeutic candidates. A lzheimer's disease (AD) poses a health problem of pandemic proportions. It is estimated that by the year 2030 there will be greater than 60 million people worldwide with AD, and $375 billion will be spent annually in the United States to care for affected individuals. The tedious and expensive process of drug discovery in AD is complicated by the fact that the causes and underlying mechanisms of the disease are still incompletely defined, and presymptomatic diagnosis is not yet in routine clinical use (1).
The canonical pathogenesis of Alzheimer's disease links the expression of apolipoprotein E e4 allele (ApoE) to amyloid precursor protein (APP) processing and Aβ peptide accumulation by a set of mechanisms that is incompletely defined. The development of a simple system that focuses not on a single variable but on multiple factors and pathways would be valuable both for dissecting the underlying mechanisms and for identifying candidate therapeutics. Here we show that, although both ApoE3 and ApoE4 associate with APP with nanomolar affinities, only ApoE4 significantly (i) reduces the ratio of soluble amyloid precursor protein alpha (sAPPα) to Aβ; (ii) reduces Sirtuin T1 (SirT1) expression, resulting in markedly differing ratios of neuroprotective SirT1 to neurotoxic SirT2; (iii) triggers Tau phosphorylation and APP phosphorylation; and (iv) induces programmed cell death. We describe a subset of drug candidates that interferes with the APP-ApoE interaction and returns the parameters noted above to normal. Our data support the hypothesis that neuronal connectivity, as reflected in the ratios of critical mediators such as sAPPα:Aβ, SirT1:SirT2, APP:phosphorylated (p)-APP, and Tau:p-Tau, is programmatically altered by ApoE4 and offer a simple system for the identification of program mediators and therapeutic candidates.
A lzheimer's disease (AD) poses a health problem of pandemic proportions. It is estimated that by the year 2030 there will be greater than 60 million people worldwide with AD, and $375 billion will be spent annually in the United States to care for affected individuals. The tedious and expensive process of drug discovery in AD is complicated by the fact that the causes and underlying mechanisms of the disease are still incompletely defined, and presymptomatic diagnosis is not yet in routine clinical use (1) .
The apolipoprotein E e4 allele (ApoE; chromosomal locus 19q13) is the single most important genetic risk factor associated with AD. This allele confers increased risk for sporadic and familial AD (2) . Individuals with two copies of the ApoE e4 allele have an approximately eightfold increased risk of AD and have a significantly lower age of onset compared with AD patients not carrying this allele (2) . Recent data indicate that the greater risk of AD associated with the ApoE4 isoform might relate to ApoE's susceptibility to proteolysis and neurotoxicity or through its role in inhibiting Aβ clearance and/or stimulating Aβ deposition, leading to plaque formation (3, 4) . Contrary to the previously reported work, one recent study provides evidence that ApoE and soluble Aβ have very minimal direct interaction, thus ApoE may influence soluble Aβ metabolism through its interactions with other receptors or transporters (5) . Thus, despite knowing for over a decade that the ApoE e4 allele is somehow contributory to the disease process, the precise molecular mechanisms underlying ApoE and APP interactions, direct or indirect, resulting in ApoE4-mediated toxicity, remain unclear.
The amyloid precursor protein, APP, has been shown to function as a molecular switch: cleavage at the β, γ, and caspase sites results in the production of four pro-AD-peptides-soluble amyloid precursor protein beta (sAPPβ) (from which N-APP is derived), Aβ, Jcasp, and C31-that mediate neurite retraction, synaptic reorganization, and ultimately programmed cell death.
In contrast, cleavage at the α site produces the trophic peptide sAPPα and the inhibitor of APP γ-site cleavage, alpha-COOHterminal fragment of APP (αCTF) (1, 6) . The decision between these two proteolytic pathways is governed at least in part by ligand binding: interaction with the axon guidance and trophic factor netrin-1 increases α-site cleavage, whereas interaction with the antitrophin Aβ inhibits α-site cleavage and increases net production of the four neurite-retractive peptides (1, 6) . According to a recent study, the level of cerebrospinal fluid (CSF) sAPPα is significantly lower in AD patients possessing one or two ApoE4 alleles than in those not possessing the ApoE4 allele (7). Therefore, it was of interest to determine whether ApoE isoforms impact this trophic-antitrophic peptide balance differentially, and, if so, by what mechanism.
Our data reveal differential effects of ApoE4 vs. ApoE3 on APP interaction, signaling, and processing and are compatible with the notion that the Alzheimer's phenotype represents an imbalance between the trophic and antitrophic signaling of APP, reflected by the ratio of the four APP-derived neurite-retractive peptides to the two APP-derived trophic peptides. Our current results show that ApoE4 interacts with high affinity with APP, shifting the processing balance in the antitrophic direction, decreasing sAPPα secretion, and reducing sAPPα/Aβ and sAPPα/ sAPPβ ratios in comparison with ApoE3. In addition, the presence of ApoE4 results in increased APP-Thr668 phosphorylation (p-APP) and Tau phosphorylation (p-Tau). Some of these ApoE4-mediated events were blocked by proteasomal inhibitors, and in a small pilot study, the proteasomal inhibitor disulfiram and a CDK inhibitor were shown to be effective in reversing some of the ApoE4-mediated effects. Furthermore, we identified Significance This manuscript links ApoE4-mediated signaling with Sirtuin function. Specifically, we show that ApoE4, but not ApoE3, reduces neuroprotective SirT1 levels. Our data support the hypothesis that neuronal connectivity, as reflected in the ratios of critical mediators such as sAPPα:Aβ, SirT1:SirT2, APP:p-APP, and Tau:p-Tau, is programmatically altered by ApoE4. Thus ApoE4, SirT1/2, p-Tau, and p-APP, all may be part of a signaling network that is affected in AD, providing a model for therapeutic candidate screening in AD drug discovery. These findings offer a unique insight into the mechanism by which ApoE4 confers risk for the development of Alzheimer's disease.
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initial therapeutic candidates-F03 and F05-that normalize some of the ApoE4 effects.
In addition to these effects on APP processing and signaling, ApoE4 expression was associated with a marked reduction in the ratio of SirT1 to SirT2, both in cultured neural cells and in the brains of patients with AD. Because SirT1 has been implicated in neuroprotection and SirT2 in neurodegeneration (8) , this effect of ApoE4 may be important from both mechanistic and therapeutic development standpoints.
Our data support the view that ApoE4 modulates the connectivity balance, as reflected in the ratios of sAPPα:sAPPβ, sAPPα:Aβ, SirT1:SirT2, APP:p-APP, and Tau:p-Tau. The network of proteins that mediates this balance thus represents a set of candidate targets for the prevention and treatment of ApoE4-associated processes such as mild cognitive impairment and AD.
Results
ApoE Isoforms Associate with APP. Although the lipidation status of ApoE affects its structure (9), it is not yet clear whether the risk associated with ApoE4 is related solely to lipidated ApoE4, to poorly lipidated ApoE4, to unlipidated ApoE4, or to a combination of these forms of ApoE4. Therefore, by transfecting and allowing cellular lipidation to occur naturally, we can assess both the unlipidated and the lipidated forms with respect to their effects on the AD phenotype. Hence our studies involved transfecting cells with ApoE4 vs. ApoE3 expression constructs.
All of the cells that we tested expressed one or more of the receptors or specific ER chaperone proteins involved in the uptake of ApoE, such as the low-density lipoprotein (LDL) receptor (∼110 kDa), LDL receptor-like protein (LRP; ∼85 kDa), or receptor-associated protein (RAP, ∼24 kDa) (Fig. S1 ). Coimmunoprecipitation (Co-IP) experiments suggested that ApoE3 and E4 associate with sAPPα (secreted in media) and APP (cell extracts) from several cell lines tested. Shown in Fig. 1 is the evidence of association between APP and ApoE isoforms in two different cell lines. Although A172 human glioblastoma cells ( Fig.  1 A and B) were transfected with only the ApoE isoforms, the H4 human neuroglioma cells ( Fig. 1 C and D) required transfection of both APP and ApoE due to low endogenous expression of APP in this cell line. Interestingly, in both paradigms, transfection of ApoE4 resulted in more than 50% reduction in the expression of sAPPα compared with ApoE3, suggesting that the presence of ApoE4 may either have blocked sAPPα formation or promoted its degradation. Immunoprecipitation (IP) of an unrelated receptor protein (TrkA) from A172 cell lysates obtained from transient cotransfections of human TrkA expression construct together with ApoE isoforms did not reveal any association with E3 or E4, suggesting specificity to the APP-ApoE interaction (Fig. S2 ).
ApoE4 Binds to APP at Endocytic pH with a Significantly Higher Affinity than ApoE3. We also confirmed the interaction of ApoE and APP by surface plasmon resonance (SPR) to measure the binding of recombinant ApoE isoforms with recombinant protein fragments of the ectodomain of APP, as well as the full ectodomain of APP 695 (eAPP ) at pHs more characteristic of intracellular compartments. Analysis of the recombinant ApoE with a calibrated Superdex S-200 size-exclusion chromatography column gave the expected molecular weight of the ApoE tetramer for both ApoE3 and ApoE4, indicating that the amounts of lipid retained were small in comparison with the mass of the protein. The E2 domain of APP and the Aβ-cognate region (trx-eAPP 290-624 ) gave an effective K D of 80 nM for ApoE4 and 300 nM for ApoE3 (Fig. 2 A and B , Table S1 , and Fig. S3 ). Although both ApoE and APP self-associate (10), the amount of ApoE-APP complex formed at equilibrium approximated the isotherm expected for a single-binding equilibrium (Fig. 2 C and D) , consistent with previous observations regarding the association of ApoE-containing VLDL particles at pH greater than 7 (11). At pH 6.5, we found a consistent trend that ApoE4 displayed tighter binding than ApoE3 independent of whether the ApoE or APP was attached to the flow cell surface. In addition, unlike previous experiments that suggested that the E1 domain of APP 751 (residues 1-207) was the major binding site for ApoE-containing particles, our results suggest that at intracellular pH, the major binding site for ApoE in the APP 695 ectodomain is within the E2 domain (residues 290-575). We did not observe significant binding to a fusion protein containing the Aβ 1-28 sequence (trx-eAPP 575-624 ) (Table S1 and Fig. S3 ).
ApoE4, but Not ApoE3, Significantly Reduces sAPPα Secretion, sAPPα/ Aβ, and sAPPα/sAPPβ Ratios. To understand the cellular consequences of ApoE-APP interactions further, we assessed the levels of sAPPα, sAPPβ, or Aβ in different cell lines. Addition of ApoE4, but not ApoE3, significantly decreased sAPPα secretion and reduced sAPPα/Aβ1-42 and sAPPα/sAPPβ ratios in A172 human glioblastoma cells (Fig. 3A) and H4 human neuroglioma cells (Fig. 3B) , respectively. ApoE4Δ is the carboxyl-terminal truncated form of ApoE4 that triggers neurotoxicity and cell death (2) . A significant ApoE4 or ApoE4Δ isoform-dependent inhibition of sAPPα secretion and reduction in the α/β ratio was observed in other neural cell lines as well (Fig. S4 ).
Differential Effects of ApoE on Sirtuin Expression in Cells and AD
Postmortem Tissue. One of the mechanisms by which ApoE4 could trigger a reduction in sAPPα levels is by inhibiting the proteolysis of APP at the α-site. Recent studies have shown that SirT1, which belongs to the Sirtuin family of NAD-dependent protein deacetylases, suppresses AD-related biochemical events in cells, primary neurons, and mouse models by directly activating transcription of ADAM10, thus increasing the levels of the neuroprotective sAPPα (8, 12, 13) .
To investigate what role ApoE has on SirT gene expression, we first performed quantitative real-time PCR in A172 cells transfected with ApoE3 or ApoE4. Our results indicated a significant down-regulation of SirT1 gene expression by ApoE4 compared with ApoE3 (Fig. 4A) . Although SirT2 gene expression was unaffected by the ApoE isoforms, there was a slight decrease in SirT6 expression by ApoE4 alone (Fig. 4A ). The data suggested that ApoE4 has a profound transcriptional effect on SirT1 expression.
To investigate the effect of ApoE isoforms on Sirtuin protein expression, we evaluated the levels of SirT1, SirT2, and SirT6 in cells and postmortem human brains. Cell extracts isolated from A172 cells transfected with ApoE3 or E4 were subjected to SDS/ PAGE and Western blotting (WB) to detect the various Sirtuins. The presence of either ApoE3 or ApoE4 resulted in a significant reduction in SirT1 levels ( Fig. 4B , Middle). In contrast, although the presence of ApoE3 resulted in a commensurate reduction in SirT2 levels, the presence of ApoE4 triggered an approximate twofold increase in SirT2 expression. The levels of SirT6 remained unchanged in ApoE-transfected cells. Thus, the ratio of SirT2: SirT1 was unaffected by ApoE3, but increased markedly-∼4.5-fold-by the expression of ApoE4 (Fig. 4B ).
To extend these cellular observations, we performed a similar analysis on postmortem temporoparietal regions of normal subjects and individuals with advanced AD pathology. As in the cell culture results, the SirT2:SirT1 ratio was increased, although in these advanced cases, this effect was solely due to a reduction in SirT1 expression ( Fig. 4C )-whether SirT2 expression was increased earlier in the pathogenetic process could not be determined from these samples. SirT6 expression was again unaltered.
Because the ApoE4-mediated reduction in SirT1 levels may in turn result in reduced sAPPα levels, it was important to determine whether the replacement of SirT1 in the presence of ApoE4 reverses the reduction in sAPPα. Following transfection of A172 cells with ApoE4 and SirT1 (1:1 and 1:2, respectively), cell culture media were collected, and the levels of sAPPα were assessed. Overexpression of SirT1 reversed the ApoE4-mediated reduction in sAPPα secretion and restored it to normal levels ( Fig. 4D) . Additionally, the cell culture media was subjected to IP with the N-terminal anti-APP antibody followed by SDS/PAGE and WB to detect sAPPα. Overexpression of SirT1 reversed the ApoE4-mediated decrease in sAPPα expression (Fig. 4E ).
Pharmacological Reversal of ApoE4-Mediated Reduction in sAPPα Levels. To determine whether the ApoE4-mediated reduction in sAPPα could be reversed by therapeutic candidates, A172 cells transfected with ApoE4 were incubated with various candidates including the pan-caspase inhibitor z-VAD, proteasomal inhibitors MG132 or epoxomicin, and disulfiram, a compound that we have previously shown to interact directly with the APP extracellular domain and increase its α-secretase cleavage (10) . The addition of ApoE4 significantly decreased sAPPα secretion; however, this effect was reversed by the proteasomal inhibitors MG132 (5 μM) and epoxomicin (5 μM) and also by disulfiram (20 μM) but not by the pan-caspase inhibitor z-VAD or the γ-secretase inhibitor DAPT ( Fig. 5 A and B) .
Using small-angle X-ray scattering (SAXS) and intrinsic fluorescence studies, we previously reported that disulfiram binds to fragments of the extracellular domain of APP (10) . We extended these observations here to show that disulfiram binds to APP 575-624 with a calculated K D of 0.6 μM (Fig. S3) ; furthermore, incubation of saturating amounts of disulfiram (5 μM) with ApoE4 decreased the binding of ApoE4 to the ectodomain of APP (APP ) by 50% ( Fig. 2E and Fig. S3 ).
Furthermore, in experiments involving screening of small molecule libraries, we also identified two therapeutic candidates-FO3 (tropisetron) and FO5 [1H-Indazole-3-carboxylicacid, N-(3S)-1-azabicyclo (2.2.2) oct-3-yL]-that reversed the ApoE4-mediated effects described above. In A172 cells transfected with ApoE4, the decrease in sAPPα was completely reversed by treatment with 1 μM FO3 (Fig. 5C) . Similarly, FO5 (1 μM) also reversed the ApoE4-mediated reduction in sAPPα secretion and restored it to normal levels ( Fig. 5D) . (Fig. S3) . Fig. 3 . ApoE4 but not ApoE3 significantly reduces sAPPα and lowers α/β ratio. A172 cells (A) and H4 cells (B) were transfected with ApoE isoforms alone or APP and ApoE isoforms, respectively. sAPPα and sAPPβ secreted into the medium and Aβ1-42 in the cell extracts were assayed as mentioned in SI Materials and Methods. Data (mean ± SE) are from four experiments performed in triplicate, *P < 0.05.
ApoE4 Triggers APP-Thr668 Phosphorylation and Tau Phosphorylation
in Cells and AD Postmortem Tissue. APP phosphorylation may be another possible mechanism by which the APP and ApoE interaction lead to decreased sAPPα secretion and α/β ratio (14, 15) . Furthermore, the microtubule-associated protein Tau and its phosphorylation play a crucial role in the pathogenesis of AD (16) . To investigate whether ApoE triggered APP and/or Tau phosphorylation, A172 cells were transfected with ApoE3 or E4. Twenty-four hours after transfection, cell extracts were subjected to IP with anti-APP antibody followed by SDS/PAGE and WB to detect p-APP and p-Tau. Increased phosphorylation of APP at Thr668 was observed in extracts isolated from cells transfected with the ApoE4 expression construct compared with ApoE3 (Fig. 6A) . The IP experiments also suggested that APP associated with Tau both in the absence and presence of ApoE (Fig.  6B) . Furthermore, increased p-Tau was observed only in those samples that were transfected with ApoE isoforms. ApoE3′s effect on p-Tau was considerably less than the effect of ApoE4 (Fig. 6B, top two panels) .
The above-mentioned cellular results prompted us to assess the relationship between ApoE and phosphorylation of APP and Tau in human AD brains (Table S2) . To do so, we initially performed ApoE genotype analysis on postmortem temporoparietal regions of normal subjects and individuals with advanced AD-like pathology ( Fig. S5 and Table S2 ). With the exception of one control and one AD individual, all were heterozygotic for the three ApoE alleles. Although the expression of APP and Tau was similar in normal and AD individuals, increased phosphorylation of APP on Thr668 residue was observed only in the extracts isolated from AD brains (Fig. 6C) . Similarly, immunoblotting with p-TauSer422 antibody revealed the presence of p-Tau in greater abundance in AD samples (Fig. 6C) . Interestingly, increased APP and Tau phosphorylation was not observed in the AD patient who was homozygous for the ApoE3 allele.
ApoE4-triggered APP Thr668 phosphorylation and Tau phosphorylation have been reported to lead to disruption of the microtubule network, impairment of axonal transport, cellular damage, and cell death (16, 17) . When A172 cells were transfected with ApoE isoforms and cell viability was measured 24 h later, cells transfected with ApoE4 were indeed found to be more susceptible to cell death compared with ApoE3 (Fig. S6) .
Pharmacological Reversal of ApoE4-Mediated APP or Tau Phosphorylation.
To determine whether increased p-APP or p-Tau may be reversed pharmacologically, we tested ApoE4-mediated APP or Tau phosphorylation in the presence of specific kinase inhibitors. CHIR99021, a GSK-3β inhibitor, reversed ApoE4-mediated reduction in sAPPα secretion and restored it to normal levels ( Fig. 7A ) and also reversed ApoE4-mediated APP phosphorylation (Fig. 7B) . Similarly, the cyclin-dependent kinase5 (CDK5) inhibitor PHA793887 also attenuated p-APP and p-Tau at all concentrations tested (Fig. 7C) .
Discussion
The amyloid precursor protein, APP, has been shown to function as a molecular switch: cleavage at the β, γ, and caspase sites results in the production of four pro-AD peptides-sAPPβ (from 1 and 1:2, respectively) , sAPPα secreted into the medium (D) was assayed as mentioned in SI Materials and Methods. Cell extracts were subjected to IP with an N-terminal anti-APP antibody followed by SDS/PAGE and WB to detect sAPPα (E). The last three panels represent ApoE, SirT1, and GAPDH (loading control) before the pull-down. Band densities of sAPPα are expressed as a percentage of sAPPα in control untransfected cells. Cell culture media were collected and either assayed for sAPPα (A) as described in SI Materials and Methods or subjected to IP with an N-terminal anti-APP antibody followed by SDS/PAGE and WB to detect sAPPα (B). FO3 and FO5 (C and D) reverse ApoE4-mediated reduction in sAPPα levels. Twenty-four hours after transfecting A172 cells with ApoE4, culture medium was changed, and F03 (C) or F05 (D) was added. After an additional 24 h, cell culture media were collected and assayed for sAPPα. Data (mean ± SE) are expressed in arbitrary units of sAPPα released into the media (*P < 0.05).
which N-APP is derived), Aβ, Jcasp, and C31-that mediate neurite retraction, synaptic reorganization, caspase activation, and ultimately programmed cell death. In contrast, cleavage at the α site produces the anti-AD trophic peptide sAPPα and the inhibitor of APP γ-site cleavage, αCTF (1, 6, 18) . The decision between these two proteolytic pathways is governed at least in part by ligand binding (1, 6, 18) . Therefore, it was of interest to determine whether ApoE isoforms impact this trophic-antitrophic peptide balance differentially, and, if so, by what mechanism(s).
Our data indicate that ApoE4 interacts with APP with nanomolar affinity, and whether via this interaction or others, ApoE4 decreases sAPPα secretion and reduces sAPPα/Aβ and sAPPα/ sAPPβ ratios. ApoE4's effect in reducing sAPPα varies from a modest but significant decrease to a near complete reduction in different cell lines. This may be due to varying levels of ApoE4 interactors that influence α-secretase activity and sAPPα levels (19) . In our study, although the effect of E4 on Aβ varied in different cell lines, the ratio of sAPPα/Aβ decreased significantly in all cell lines that we tested, indicating that the ratio may serve as a more reliable indicator of the trophic-antitrophic peptide balance.
Our data are consistent with earlier reports demonstrating that the level of CSF sAPPα is significantly lower in AD patients possessing one or two ApoE4 alleles than in those not possessing the ApoE4 allele (7), treatment of human SH-SY5Y neuroblastoma cells with ApoE4 results in decreased secretion of sAPPα (20) , and secretion of sAPPα is differentially affected by distinct ApoE isoforms as a functional consequence of the APPApoE interaction (21) .
The mechanism by which ApoE4 decreases sAPPα secretion remains unclear. Recent studies point to SirT1, which belongs to the Sirtuin family of NAD-dependent protein deacetylases, as being a transcriptional activator of ADAM10. SirT1 suppresses AD in cells, primary neurons, and mouse models by activating transcription of ADAM10, thus increasing the levels of the neuroprotective sAPPα. In addition, SirT1 reduces production of β-amyloid (8, 12) . Several studies point to opposing effects of SirT1 and SirT2: although SirT1 activation is associated with neuroprotection, SirT2 up-regulation is toxic to neuronal cells (22, 23) . This led us to investigate the effect of ApoE isoforms on SirT levels. Although ApoE3 down-regulated SirT1 mRNA, there was a greater reduction in ApoE4-mediated SirT1 mRNA levels. Furthermore, the ApoE4-mediated reduction in SirT1 mRNA levels correlated strongly with a reduction in SirT1 protein levels, unlike for SirT2, whose protein expression did not correlate with the mRNA expression.
Although the effect of SirT1 in increasing sAPPα has been noted previously (8, 12) , our work links ApoE4 to reduced sAPPα and a general shift of APP proteolysis away from the trophic peptides sAPPα and αCTF and toward the production of Aβ, via an effect on SirT1. The overexpression of SirT1 in the presence of ApoE4 prevented the phenotype observed with ApoE4, providing further support for our in vitro model.
Contrary to effects on SirT1 mRNA levels, neither isoform of ApoE affected SirT2 or SirT6 mRNA and protein levels (the decrease in SirT6 mRNA expression in ApoE4 transfected cells was not significant). The question arises as to how ApoE4-mediated SirT2 protein was increased posttranscriptionally. One possibility is that ApoE4 may be promoting an increased rate of SirT2 protein translation without affecting SirT2 transcription. Other explanations include the differential regulation of SirT2 mRNA expression, stability, and degradation compared with its protein expression, stability, and degradation, for example, via miRNA effects (24) .
Furthermore, our results in cells, showing that ApoE4 expression is associated with a decrease in SirT1 and an increase in SirT2, support the notion that the set of alterations observed with ApoE4 expression may result at least in part from a reduction in SirT1 and an increase in SirT2. The results with the human AD brain-a decrease in SirT1-mirror our results in cells with ApoE4 and are in agreement with an earlier study (13) . The lack of an associated increase in SirT2 was not observed in the AD brains, but this may have been due to the end-stage nature of the pathological samples. Our results suggest that ApoE4 causes a "Sirtuin inversion" such that SirT2 dominates SirT1, leading to a neurite-retractive and programmed cell death signal (22, 23) . Reducing the SirT2:SirT1 expression ratio either by increasing the levels of SirT1 mRNA or protein or decreasing the levels of SirT2 protein may therefore serve as a feasible therapeutic approach. Because the SirT1 levels (mRNA and protein) were significantly reduced by ApoE4, another attractive therapeutic approach would be to screen for drugs that normalize the levels of SirT1 mRNA or protein. One question raised by these results is whether the evolutionary development of ApoE3 from the primordial ApoE4 in humans offered some advantage that is indeed associated with an alteration in the SirT1:SirT2 expression ratio (25) .
Our studies on ApoE4-mediated APP and Tau phosphorylation are compatible with other studies that also suggest that ApoE4-mediated APP-Thr668 phosphorylation or Tau phosphorylation alters cellular APP processing, thereby affecting sAPPα or sAPPβ secretion and sAPPα/Aβ ratio (14) (15) (16) . Increased p-APP and pTau were observed only in those samples that were transfected Fig. 6 . ApoE4 triggers APP-Thr668 phosphorylation and Tau phosphorylation. (A and B) Twenty-four hours after transfecting A172 cells with ApoE4, cell extracts were subjected to IP with anti-APP antibody followed by SDS/PAGE and WB to detect p-APP (A), p-TauSer422 (B, Top), p-TauSer409 (B, Middle), or Tau (B, Bottom). The last two panels in A represent ApoE and GAPDH (loading control) or APP and GAPDH (loading control) before the pull-down (B). (C) p-APP and p-Tau in AD. A total of 100 μg each of temporoparietal extracts isolated from normal and AD brains (Table S2) were examined by WB using APP, p-APPThr668, Tau, and p-TauSer422 antibodies. Isoform genotyping of ApoE was performed as described in SI Materials and Methods (Fig. S5) . Fig. 7 . Inhibition of GSK-3β or CDK5 decreases p-APP or p-Tau. (A) Culture media from ApoE-transfected A172 cells exposed to the GSK-3β inhibitor CHIR9902 were collected and assayed for sAPPα as described in SI Materials and Methods. sAPPα values are depicted as a percentage of control. Data (mean ± SE) are from three independent experiments performed in triplicate (*P < 0.05). (B and C) Extracts were prepared from ApoE-transfected A172 cells exposed to the GSK-3β inhibitor CHIR9902 (B) or CDK5 kinase inhibitor PHA793887 (C) and subjected to SDS/PAGE and WB to detect p-APP (B) or APP, p-APP, Tau, and p-Tau (C).
with ApoE4. The results with human AD brains-an increase in APP and Tau phosphorylation-mirror our results in cells. However, the increased APP and Tau phosphorylation pattern was not observed in one AD subject with an E3/E3 profile. With just n = 1, it is difficult to explain the lack of increased APP and Tau phosphorylation. If further samples support this observation, it may suggest that there may be events independent of APP or Tau phosphorylation that trigger the AD pathogenesis.
The mechanism by which ApoE4 triggers Tau phosphorylation is not clear. It has been reported that SIRT1 deficiency leads to hyperacetylation of Tau and accumulation of p-Tau and Aβ in mouse models of AD and in AD patients (26) . Our results showing that ApoE4 expression is associated with a decrease in SirT1 mRNA and protein may partly explain the increase in pTau. Our results also demonstrated the interaction of APP with Tau and p-Tau. Thus, the trimeric complex of ApoE4-APP-Tau/ p-Tau may represent one mediator of the pathological changes associated with AD (16, 17, 27) .
Disulfiram, which we have reported to interact directly with APP (10), inhibited the ApoE4-mediated events. Interestingly, recent reports have shown that the previously observed antitumoral activity of disulfiram could be attributed to its potent inhibition of the ubiquitin-proteasome activity (28) . Additionally, ApoE4-mediated reduction in sAPPα levels and increased p-APP and p-Tau were all reversed by the kinase inhibitors CHIR99021 and PHA793887. ApoE4 has been reported to activate GSK-3β more than other isoforms, and GSK-3β is believed to mediate phosphorylation of APP at Thr668 (20) . In conjunction, CDK5 has also been proposed to be central to the phosphorylation of APP and Tau (29) . Furthermore, in experiments involving the screening of chemical compound libraries, we identified two therapeutic candidates-FO3 and FO5-that prevent the ApoE4-mediated effects. Further secondary assay testing of these therapeutic candidates in neuronal cultures generated from platelet-derived growth factor B chain promoter-driven amyloid precursor protein (PDAPP) mice (huAPP Swe/Ind ), together with a battery of in vivo tests in PDAPP mice, are in progress.
ApoE3′s effect on sAPPα was found to be less than the effect of ApoE4; furthermore, ApoE3 did not alter the SirT2/T1 ratio, nor did it have the same effect on p-Tau, p-APP, or cell death induction. Thus, it is clear that ApoE4 exerts isoform-specific signaling events that affect APP proteolysis and signaling, downstream kinase activity, and Sirtuin expression. These results are compatible with the notion that ApoE4-mediated signaling affects an endogenous program that mediates synaptic plasticity balance. Although the complete sequence of events initiated by ApoE4 leading finally to neurodegeneration remains to be defined, our studies demonstrate that ApoE4 triggers alternative cellular APP processing favoring the amyloidogenic route. The results also indicate that ApoE4, p-Tau, p-APP, and SirT1 all may be part of a signaling network that is affected in AD, providing a medium-throughput model for therapeutic candidate screening in AD drug discovery.
Materials and Methods
All experiments were performed in several different cell lines, some of which required transfection of ApoE isoforms alone and some that required transient transfections of APP and ApoE isoforms. Experimental details about the cell lines, cDNA constructs, transient transfection procedures, cellular extraction, immunoprecipitation, electrophoresis, western blotting and antibodies used for the experiments are provided in SI Materials and Methods. sAPPα or sAPPβ secreted into the cellular media were determined with the AlphaLISA sAPPα and sAPPβ immunoassay research kits as described in SI Materials and Methods. The Aβ1-42 or 1-40 was determined from media or cells using a sandwich ELISA kit as described in SI Materials and Methods. PCR primers, RNA isolation, real time PCR conditions, analysis of mRNA levels, postmortem human brain tissue extraction, ApoE isoform genotyping and SPR data are provided in SI Materials and Methods.
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SI Materials and Methods
Cell Culture Conditions and Transfections. All experiments were performed in several different cell lines, some of which required transient transfection of apolipoprotein E (ApoE) isoforms alone and some that required transfections of amyloid precursor protein (APP) and ApoE isoforms. Cell lines included HN33 (mouse hippocampal neuron × N18TG2 neuroblastoma), HEK-293T, SH-SY5Y, and H4 human neuroglioma cells that required transient transfection of APP and ApoE isoforms and A172 human glioblastoma cells that expresses APP endogenously that required transient transfection of only ApoE isoforms. Cells were cultured in DMEM containing 10% (vol/vol) FBS and 1% (vol/vol) penicillin/streptomycin. pcDNA3-APP695 was as described previously (1) . Human ApoE cDNA constructs were generously provided by Yadong Huang (Gladstone Institute of Cardiovascular Disease, University of California, San Francisco). The PCR product encoding modified ApoE4Δ (amino acids 1-272) was subcloned into a pFLAG-CMV-3 vector (Sigma) containing an amino-terminal FLAG fusion peptide with the protein expression being driven by the human cytomegalovirus immediate-early promoter (2-4). All DNA constructs were confirmed by sequence analysis.
Transient transfection of cells with Lipofectamine 2000 (Invitrogen) or FuGENE-6 or X-tremeGENE (both from Roche) was performed as described earlier (5, 6) or according to the manufacturer's instructions. The transfection efficiency using these conditions was about 50-70%. Cells were transfected with ApoE alone or APP/ApoE constructs.
Cell Extracts, Immunoprecipitation, and Western Blotting. Following transfection of cells with APP and ApoE isoforms or ApoE isoforms alone, culture media and cell extracts were collected. Whole cell extracts were prepared as described earlier (6, 7) . Briefly, cells were collected and resuspended in cell lysis buffer (500 mM Hepes, pH 7.6, 250 mM NaCl, 0.1% Nonidet P-40, 5mM EDTA) containing complete miniprotease inhibitors (Roche). Resuspended cells were sonicated three times for 30 s each, and unbroken cells and membrane debris were removed by centrifugation at 4°for 15 min at 20,000 × g. Typically, 100 μg of cell extract was loaded for SDS/ PAGE and Western blot analysis as previously described (6, 7) . Culture media and cell extracts (150-200 μg protein) were subjected to immunoprecipitation (IP) with an N-terminal anti-APP antibody that recognizes soluble amyloid precursor protein alpha (sAPPα) or 5A3/1G7 mixed monoclonal antibody (recognizing the ectodomain of APP) or anti-CT-15-APP antibody. The immunoprecipitated proteins were subjected to SDS/PAGE and Western blotting (6, 7) . Enhanced chemiluminescence detection of the proteins was performed with Pierce ECL detection reagent (Thermo Scientific).
Antibodies. The following APP antibodies were used in the present studies: 5A3/1G7 mixed monoclonal antibody (recognizing the ectodomain of APP) (8, 9) ; APP-CT15 polyclonal antibody (both kindly provided by Edward Koo, University of California, San Diego); APP-6E10 monoclonal antibody (Covance); and N-terminal APP polyclonal antibody (Sigma). Other antibodies included ApoE antibody (Sigma), APP-phosphoThr668 antibody (Cell Signaling), Tau and phosphorylated (p)-Tau antibodies (Invitrogen and Cell Signaling), and SirT antibodies (Cell Signaling). All HRP-conjugated secondary antibodies were purchased from Amersham/GE Healthcare or Santa Cruz Biotechnology.
sAPPα, sAPPβ, and Aβ Assay. sAPPα or sAPPβ secreted into the cellular media was determined with the AlphaLISA sAPPα and sAPPβ immunoassay research kits (Perkin Elmer) according to the manufacturer's protocol with some modifications (10, 11) . The standards, blanks, and media were diluted with the buffer provided in the kit and added to the plate. During the first incubation step, the analyte was captured either by an antibody recognizing the α-secretase cleavage site at sAPPα C terminus (clone 2B3) or the sAPPβ C terminus and by a second biotinlabeled antibody specific to the N-terminal part of sAPP (common for both sAPPα and sAPPβ). In the second incubation step, the biotinylated anti-analyte antibody was bound to the streptavidin-coated donor beads. At the end of this reaction, the plates were read on an EnSpire Alpha 2390 multilabel plate reader equipped with the AlphaScreen module. The Aβ1-42 or 1-40 was determined from media or cells using Invitrogen's sandwich ELISA kit as described previously (10) (11) (12) . The levels of Aβ were quantified from a standard curve and normalized to total cellular protein.
Quantitative Real-Time PCR. To analyze the mRNA levels of Sirtuin T1 (SirT1), SirtT2, and SirT6, real-time PCR was performed on first-strand cDNAs. Primers for SirT1, SirT2, and SirT6 were designed using the Roche universal probe library system; a custom assay and the primers were synthesized by Integrated DNA Technology. Real-time PCR was performed in SYBR Green master mix (Roche) with the corresponding primer sets. A172 cells were transfected with ApoE3 or ApoE4 cDNA, and after 24 h, the cells were trypsinized and collected. Total RNA was isolated using High Pure RNA isolation kit (Roche). RNA concentrations were measured using the NanoDrop ND-1000 spectrophotometer, and 1 μg of RNA from untransfected and each transfected sample was reverse transcribed. The real-time PCR cycling was performed on the Light Cycler 480 (Roche) using white Light Cycler480 384-multiwell plates. The melting curves of PCR products were monitored to ensure that a single melting curve was obtained. For analysis of the real-time PCR data, δCt values of samples were normalized to values obtained for GAPDH, which was assayed simultaneously. Relative quantification using the Delta Delta Ct method was adopted to calculate the relative quantity of SirT1, SirT2, and SirT6 levels.
Restriction Isotyping of Human ApoE. We used restriction enzyme isoform genotyping to identify the ApoE alleles as described previously (13, 14) . The method involved using primer pairs to amplify the ApoE gene sequence containing amino acid positions 112 and 158. The amplification products were later digested with HhaI and subjected to electrophoresis on polyacrylamide gels. Each of the isoforms was distinguished by a unique combination of HhaI fragment sizes (Fig. S5 ) that enabled explicit typing of all homozygotic and heterozygotic combinations.
Human Autopsy Material. Dissected frozen tissues representing different regions of the brain were provided by Stephen DeArmond (School of Medicine, University of California, San Francisco), and research was conducted in compliance with policies and principles contained in the Federal Policy for the Protection of Human Subjects. Eleven postmortem human brains [five normal and six with Alzheimer's disease (AD)] were used in this study. Limited information (sex, age at death, and pathology status) that was available only on a subset of samples is provided in Table S2 . Restriction enzyme isoform genotyping to identify the ApoE alleles of each sample was performed as described above. Samples for SDS/PAGE and Western blots were prepared as described earlier (15) . Samples (100 μg) were added to reducing sample buffer and heated for 10 min at 70°C before subjecting them to SDS/PAGE. Surface Plasmon Resonance. Thioredoxin (trx)-fusion proteins containing ApoE3 (trx-ApoE3) and ApoE4 (trx-ApoE4) was expressed and purified as described previously (16) . In addition, four fusion proteins containing different fragments of APP were expressed and purified as described previously (17) . Escherichia coli thioredoxin (Sigma Chemicals) was purified using size-exclusion chromatography. Proteins were biotinylated using the EZ-Link Sulfo-NHS-SS-Biotin Biotinylation Kit (Thermo Scientific) following the instructions to produce one to two biotins per molecule.
For the ApoE-binding experiments, avidin (Thermo Scientific) was immobilized on a CM5 biacore chip via a standard amine coupling protocol (Biacore Handbook). Biotinylated proteins were loaded onto the chips to create two chips: one with an avidinonly reference channel (FC1), thioredoxin (FC2), ApoE3 (FC3), and ApoE4 (FC4) and one chip with an avidin-only reference channel (FC1), MBP-eAPP (FC2, FC3) , and eAPP 230-624 (FC4). Nonbiotinylated proteins were also dialyzed against 20 mM phosphate, pH 6.5, 125 mM NaCl, and 0.005% Tween-20 (PBST) and then concentrated to between 0.5 and 2.0 mg/mL The last dialysis buffer was filtered with a 22-μM filter and used as running buffer in the surface plasmon resonance (SPR) experiments. The maximal saturation for each concentration of protein was estimated by modeling the association phase with either a single phase association or two phase association model in PRISM (Graphpad). The K D, eff was calculated using the predicted plateaus for each concentration and a single-binding site model.
For the competition experiment, varying concentrations of disulfiram were incubated with either 0.15 or 0.075 μM ApoE4 in 20 mM phosphate, pH 6.5, 125 mM NaCl, and 1% DMSO before being pumped through the chip. For disulfiram-APP binding experiments, Trx-eAPP 575-624 or thioredoxin was coupled to the CM5 biacore chips using standard amine coupling techniques. The disulfiram was diluted from a 10 mM solution in DMSO to 50 μM in 1% DMSO, 20 mM sodium phosphate, pH 6.5, 125 mM sodium chloride, and 0.005% Tween and then serially diluted by 1.5 for 10 steps.
Statistical Analysis. Statistical significance for all of the tests assessed by calculating the P values and defined as P < 0.05 was calculated by one-way ANOVA followed by Newman-Keuls multiple comparisons post hoc testing. . A172 cells were transfected with TrkA and ApoE isoforms. Twenty-four hours after transfection, cell pellets were collected and lysed, and extracts were prepared. Cell extracts were subjected to immunoprecipitation (IP) with anti-TrkA antibody followed by SDS/PAGE and Western blotting (WB) to detect TrkA or ApoE4 protein expression. The last panel represents endogenous GAPDH (loading control) before the pull-down. Lane 1 represents the extract loaded before the pull down to identify the TrkA and ApoE. were transfected with APP and ApoE isoforms. Twenty-four hours after transfection, sAPPα and sAPPβ secreted into the medium were determined with the AlphaLISA sAPPα and sAPPβ immunoassay research kit as mentioned in SI Materials and Methods. Aβ1-40 in the HEK-293T cell extracts (B) was detected with a sandwich ELISA as mentioned in SI Materials and Methods. Data (mean ± SE) are from four experiments performed in triplicate, *P < 0.05. Fig. S5 . Restriction genotyping of human ApoE. Isoform genotyping of ApoE was performed as described in SI Materials and Methods. DNA isolated from normal and AD brain tissue was subjected to PCR to amplify the ApoE sequence containing amino acid positons 112 and 158. The 244-bp amplified sequence was digested with Hha1 and separated on a polyacylamide gel. The depicted figure is a sketch representing the gel-separated products of ApoE amplification and Hha1 digestion of the DNA. A 35-bp fragment is common to all genotypes. With the exception of this fragment, each genotype revealed unique combinations of Hha1 fragment sizes. Each of the samples from heterozygotic combinations contained both sets of fragments from each ApoE allele. Fig. S6 . A172 cells were transfected with ApoE isoforms, and 36 h later, cell viability was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay. Surviving and dead cells were counted and data normalized to untreated nontransfected control levels set to 100%. Data (mean ± SE) are from three independent experiments performed in triplicate, *P < 0.05. The sensograms corresponding to the table entries are shown in Fig. 2 and Fig. S3 . ND, not determined; NS, not signficant binding. *Molecular weight of the monomer. † Molecular weight estimated by size-exclusion chromatography. This molecular weight is consistent with previous findings that nonlipidated apoE being a tetramer in solution. 
